ME Therapeutics Holdings, Inc. Statistics
ME Therapeutics Holdings, Inc. (METX) Stock Statistics & Valuation Metrics
Total Valuation
ME Therapeutics Holdings, Inc. has a market cap or net worth of CAD 31.55M. The enterprise value is CAD 51.18M.
- Market Cap
- CAD 31.55M
- Enterprise Value
- CAD 51.18M
Share Statistics
ME Therapeutics Holdings, Inc. has 30,049,494 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 30,049,494
- Owned by Insiders
- 16.21%
- Owned by Institutions
- ―
Financial Efficiency
ME Therapeutics Holdings, Inc.’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
- Return on Equity (ROE)
- ―
- Return on Assets (ROA)
- ―
- Return on Invested Capital (ROIC)
- ―
- Return on Capital Employed (ROCE)
- ―
- Revenue Per Employee
- ―
- Profits Per Employee
- ―
- Employee Count
- 0
- Asset Turnover
- ―
- Inventory Turnover
- ―
Income Statement
In the last 12 months, ME Therapeutics Holdings, Inc. had revenue of ― and earned -57.46K in profits. Earnings per share was ―.
- Revenue
- ―
- Gross Profit
- ―
- Operating Income
- -60.28K
- Pretax Income
- ―
- Net Income
- -57.46K
- EBITDA
- -57.46K
- Earnings Per Share (EPS)
- ―
Stock Price Statistics
- Beta
- 1.19
- 52-Week Price Change
- -73.75%
- 50-Day Moving Average
- 1.94
- 200-Day Moving Average
- 2.29
- Relative Strength Index (RSI)
- 37.84
- Average Volume (3m)
- 4,724
Important Dates
ME Therapeutics Holdings, Inc. upcoming earnings date is Dec 02, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Jun 26, 2026
- Next Earnings Date
- Dec 02, 2026
- Ex-Dividend Date
- ―
Balance Sheet
ME Therapeutics Holdings, Inc. has ― in cash and marketable securities with CAD 0.00 in debt, giving a net cash position of ― billion.
- Cash & Marketable Securities
- ―
- Total Debt
- CAD 0.00
- Net Cash
- ―
- Net Cash Per Share
- ―
- Tangible Book Value Per Share
- ―
Analyst Forecast
The average price target for ME Therapeutics Holdings, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -5.48%

